Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Non Operating Income (2016 - 2025)

Tg Therapeutics has reported Non Operating Income over the past 10 years, most recently at $1.1 million for Q4 2025.

  • Quarterly results put Non Operating Income at $1.1 million for Q4 2025, down 94.2% from a year ago — trailing twelve months through Dec 2025 was -$2.7 million (down 134.9% YoY), and the annual figure for FY2025 was $10.8 million, up 40.3%.
  • Non Operating Income for Q4 2025 was $1.1 million at Tg Therapeutics, up from -$3.5 million in the prior quarter.
  • Over the last five years, Non Operating Income for TGTX hit a ceiling of $19.5 million in Q4 2024 and a floor of -$8.3 million in Q4 2022.
  • Median Non Operating Income over the past 5 years was -$1.4 million (2021), compared with a mean of -$326250.0.
  • Peak annual rise in Non Operating Income hit 1367.49% in 2024, while the deepest fall reached 385.62% in 2024.
  • Tg Therapeutics' Non Operating Income stood at $5.2 million in 2021, then tumbled by 257.44% to -$8.3 million in 2022, then soared by 81.35% to -$1.5 million in 2023, then soared by 1367.49% to $19.5 million in 2024, then plummeted by 94.2% to $1.1 million in 2025.
  • The last three reported values for Non Operating Income were $1.1 million (Q4 2025), -$3.5 million (Q3 2025), and $2.8 million (Q2 2025) per Business Quant data.